• New IDSA guidelines to treat drug resistant gram-negative bacteria

  • 2024/09/02
  • 再生時間: 39 分
  • ポッドキャスト

New IDSA guidelines to treat drug resistant gram-negative bacteria

  • サマリー

  • Drug resistance to antibiotics continues to escalate. This week we do a deep dive into the Infectious Disease Society of America's (IDSA) brand new guidance on the treatment of antimicrobial resistant gram-negative infections.

    The GameChanger
    The new IDSA guidelines provide critical, evidence-based recommendations for managing drug-resistant gram-negative infections. The guidance offers health care providers clear strategies to improve outcomes and reduce the emergence of resistance.

    Host
    Jen Moulton, BSPharm

    President, CEimpact

    Guests
    Geoff Wall, PharmD, BCPS, FCCP, BCGP

    Professor of Pharmacy Practice, Drake University
    Internal Medicine/Critical Care, UnityPoint Health

    Amanda Bushman, PharmD,BCPS-AQ ID, BCIDP, FIDSA
    Infectious Disease Pharmacist
    UnityPoint Health

    Tony Mannum, PharmD
    PGY2 Infectious Disease Resident
    UnityPoint Health

    Reference
    IDSA Guidelines for treating resistant gram negative organisms

    Pharmacists, REDEEM YOUR CPE HERE!
    CPE is available to Health Mart franchise members only
    To learn more about Health Mart, click here: https://join.healthmart.com/

    CPE Information

    Learning Objectives
    Upon successful completion of this knowledge-based activity, participants should be able to:
    1. Identify effective strategies for treating urinary tract and systemic infections caused by Extended-Spectrum Beta-Lactamase (ESBL)-producing organisms.
    2. Discuss appropriate therapeutic agents for infections caused by AmpC beta-lactamase-producing bacteria, ensuring choices minimize the risk of resistance development during treatment.

    0.05 CEU/0.5 Hr
    UAN: 0107-0000-24-251-H01-P
    Initial release date: 09/02/2024
    Expiration date: 09/02/2025
    Additional CPE details can be found here.

    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

Drug resistance to antibiotics continues to escalate. This week we do a deep dive into the Infectious Disease Society of America's (IDSA) brand new guidance on the treatment of antimicrobial resistant gram-negative infections.

The GameChanger
The new IDSA guidelines provide critical, evidence-based recommendations for managing drug-resistant gram-negative infections. The guidance offers health care providers clear strategies to improve outcomes and reduce the emergence of resistance.

Host
Jen Moulton, BSPharm

President, CEimpact

Guests
Geoff Wall, PharmD, BCPS, FCCP, BCGP

Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Amanda Bushman, PharmD,BCPS-AQ ID, BCIDP, FIDSA
Infectious Disease Pharmacist
UnityPoint Health

Tony Mannum, PharmD
PGY2 Infectious Disease Resident
UnityPoint Health

Reference
IDSA Guidelines for treating resistant gram negative organisms

Pharmacists, REDEEM YOUR CPE HERE!
CPE is available to Health Mart franchise members only
To learn more about Health Mart, click here: https://join.healthmart.com/

CPE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Identify effective strategies for treating urinary tract and systemic infections caused by Extended-Spectrum Beta-Lactamase (ESBL)-producing organisms.
2. Discuss appropriate therapeutic agents for infections caused by AmpC beta-lactamase-producing bacteria, ensuring choices minimize the risk of resistance development during treatment.

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-251-H01-P
Initial release date: 09/02/2024
Expiration date: 09/02/2025
Additional CPE details can be found here.

New IDSA guidelines to treat drug resistant gram-negative bacteriaに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。